Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Last revisionBoth sides next revision | ||
| content:pyridoxal_5_-phosphate-dependent_epilepsy [2024/03/17 21:40] – [Standardized Vitamin B6 Trial] biju.hameed@gmail.com | content:pyridoxal_5_-phosphate-dependent_epilepsy [2024/03/24 21:08] – [Standardized Vitamin B6 Trial] biju.hameed@gmail.com | ||
|---|---|---|---|
| Line 20: | Line 20: | ||
| ==== Standardized Vitamin B6 Trial ==== | ==== Standardized Vitamin B6 Trial ==== | ||
| - | * A standardized vitamin B6 trial [Wilson et al 2019] may raise suspicion regarding PNPO deficiency | + | * A standardized vitamin B6 trial[(: |
| * 40% of individuals with PNPO deficiency are responsive to pyridoxine (PN) and seizures. In a majority of these patients seizures will remit within 1 to 3 days, but it could take upto several days in some cases | * 40% of individuals with PNPO deficiency are responsive to pyridoxine (PN) and seizures. In a majority of these patients seizures will remit within 1 to 3 days, but it could take upto several days in some cases | ||
| * 60% of individuals with PNPO deficiency who are pyridoxal 5' | * 60% of individuals with PNPO deficiency who are pyridoxal 5' | ||
| Line 38: | Line 38: | ||
| * there are no biomarkers to differentiate from Pyridoxal 5' | * there are no biomarkers to differentiate from Pyridoxal 5' | ||
| + | ==== References ==== | ||